Eyeworld

EW NEWS & OPINION 10 even better friends. It has been a tremendous honor and privilege to act as medical co-ed- itor of EyeWorld. The genesis of EyeWorld began with the tremen- dous insight of the ASCRS executive committee and David Karcher, exec- utive director of ASCRS, to develop a society-sponsored scientific and clin- ically relevant monthly magazine. In keeping with the original fore- sight and commitment of the first EyeWorld medical editor, Marguerite McDonald, M.D., of having at least two sources for every article in order to minimize bias, EyeWorld devel- oped and has flourished since. Today EyeWorld is circulated to over 22,000 ophthalmologists and ophthalmolo- gists-in-training in over 100 coun- tries. With its global distribution to international ASCRS members, EyeWorld has the broadest physician circulation of any domestic oph- thalmic publication. It gives me great pride to be a part of the her- itage that has seen such tremendous growth and acceptance of a maga- zine whose purpose is the promulga- tion of information that is focused on clinical pearls, surgical tech- niques, ophthalmic news, and prac- tice management issues critical to cataract and refractive surgeons worldwide. I am excited that with the con- clusion of our tenure, EyeWorld is being reorganized under the leader- ship of the new chief medical editor, David F. Chang, M.D., clinical pro- fessor of ophthalmology, University of California, San Francisco. He will be joined by his newly appointed as- sociate editors: Bonnie An Hender- son, M.D., assistant clinical profes- sor of ophthalmology, Harvard Medical School, cataract editor; Edward J. Holland, M.D., professor of ophthalmology, University of Cincinnati, cornea editor; Reay H. Brown, M.D., clinical professor, Emory University, Atlanta, glaucoma editor; Kerry D. Solomon, M.D., di- rector, Carolina Eyecare Research In- stitute, Carolina Eyecare Physicians, refractive editor; and John A. Vukich, M.D., surgical director, Davis Duehr Dean Center for Refrac- tive Surgery, Madison, Wis., interna- tional editor. This reorganization brings not only new faces to EyeWorld, but also new levels of en- ergy, ideas, and innovation. What a terrific team of talent has been as- sembled! Finally, to the readership of EyeWorld and the members of ASCRS, thank you for all your won- derful ideas, articles, and dialogue over our tenure. EyeWorld is your magazine, and I am sure that the new editors will be just as happy to hear from you as we were. Let the ar- ticles you read energize you and stimulate your thinking as you con- sider the options for the future of ophthalmology and your practice. I encourage and challenge you to help make your magazine better by con- tributing your ideas and suggestions. Being EyeWorld medical co-editor is one of the true highlights of my ca- reer, and I am honored to be part of the legacy that will always be known as EyeWorld. April 2011 Passing continued from page 3 Post-meeting continued from page 9 by Terry Kim, M.D., chair, ASCRS cornea clinical committee TFOS publishes report on the diagnosis and management of MGD T he Tear Film and Ocular Surface Society (TFOS, www.tearfilm.org) recently published the findings of the International Workshop on Meibomian Gland Dysfunction (www.tearfilm.org/mgdworkshop/index.html) in Investigative Ophthalmology and Visual Sci- ence. 1-9 Similar to the Dry Eye Workshop (DEWS), the goal of this group of over 50 clin- ical and basic research experts was to provide consensus guidelines on the diagnosis and management of meibomian gland dysfunction (MGD) based on peer-reviewed literature and evidence. This landmark publica- tion is divided into nine sections that focus on the various subcommit- tee assignments (i.e., definition and classification, anatomy and physiology, epidemiology and risk factors, etc.) to help develop a better understanding of the healthy and dysfunctional meibomian gland and elucidate the impact of MGD on dry eye disease. The report states that MGD is probably the "most frequent form of dry eye disease" with an enormous impact on patient general health, quality of life, and vision. It describes MGD as a common chronic condition characterized by degrees of ductal obstruction and abnormalities in glandular secretions, leading to an unstable and rapidly evaporating tear film, bacterial overgrowth, and "ocular surface inflammation and damage." The subcommittee re- port on management and treatment provides an excellent overview of current and future medical and surgical treatments, divides MGD into four stages based on symptoms and signs, and provides practical, evi- dence-based, and organized treatment guidelines based on severity. 8 In addition to the well-known practices of lid hygiene with warm com- presses and massage and oral tetracycline derivatives for more severe dis- ease, the treatment algorithm includes the importance of topical azithromycin and topical lipid-based lubricants as well as omega-3 fatty acid supplementation as first-line therapy for all patients with sympto- matic disease. The workshop underscores the relative paucity of stan- dardized clinical trials for MGD and recommends a variety of strategies for designing, implementing, and prioritizing these trials to further ad- vance our care of these patients. The ASCRS cornea clinical committee applauds and congratulates the work of TFOS, and we encourage all cli- nicians to read this report to improve their diagnosis and treatment of this prevalent and important disease. References 1. Nichols KK. The international workshop on meibomian gland dysfunction: introduction. Invest Oph- thalmol Vis Sci. 2011 Mar 30;52(4):1917-21. 2. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The inter- national workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9. 3. Nelson JD, Shimazaki J, Benitez-Del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN. The inter- national workshop on meibomian gland dysfunction: report of the definition and classification sub- committee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1930-7. 4. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dys- function: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1938-78. 5. Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, Glasgow BJ. The inter- national workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1979-93. 6. Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1994-2005. 7. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, Yee R, Yokoi N, Arita R, Dogru M. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. In- vest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49. 8. Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on man- agement and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2050-64. 9. Asbell PA, Stapleton FJ, Wickström K, Akpek EK, Aragona P, Dana R, Lemp MA, Nichols KK. The inter- national workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2065-85. Keratorefractive Winner: P186 Enhanced Sensitivity to Detect Mild Abnormality in Asymmetric Keratoconus; Marcella Salomão, M.D.; co-au- thors: Renato Ambrósio Jr., M.D., Ph.D., Bruno de Freitas Valbon, M.D., Isaac C. Ramos, M.D., Ana Laura C. Canedo, M.D., Leonardo N. Pimentel, M.D., Diogo L. Caldas, M.D. Cornea Winner: P229 Fellow Eye Compari- son of DSAEK and DMEK; Frederico P. Guerra, M.D.; co-authors: Marianne O. Price, Ph.D., Francis W. Price Jr., M.D. Pediatric Winner: P282 Long-Term Follow-up of Impact of Corticocleaving Hy- drodissection on Posterior Capsule Opacification After Pediatric Cataract Surgery; Samaresh Srivastava, D.N.B.; co-authors: Vaishali Vasavada, M.S., Sajani K. Shah, M.S., Rupal H. Trivedi, M.D., Abhay R. Vasavada, M.S., F.R.C.S., Mamidipudi R. Praveen, M.S. Glaucoma Winner: P292 Analysis of Biome- chanical Waveform Measurement Associated With Glaucoma Progres- sion; Seungjoo Ha, M.D. Retina Poster of Interest: P314 Myopic Choroidal Neovascularisation: Factors Affecting Treatment Out- comes; Colin S. Tan, M.D. Supplementary Winner: P322 Effects of Smoking on Human Lens Epithelial Cells; Jae Woong Koh, M.D., Ph.D.; co-au- thors: Gil Joong Yoon, M.D., Ph.D., Nang Hee Song, M.D.

• Cover